On 25 January 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Shingrix, intended for prophylaxis of herpes zoster. The applicant for this medicinal product is GlaxoSmithkline Biologicals SA.
Shingrix will be available as a powder and suspension liquid to be made into a suspension for injection. The active substance of Shingrix is varicella zoster virus glycoprotein E antigen (VZV gE) (ATC code: J07BK03). In Shingrix, VZV gE is combined with an adjuvant (AS01B), and is designed to induce antigen-specific cellular and humoral immune responses in individuals with pre-existing immunity against varicella zoster virus.
The benefits with Shingrix are its ability to significantly decrease the incidence of herpes zoster and consequently of post-herpetic neuralgia compared with placebo. The most common side effects are pain at the injection site, myalgia, fatigue and headache.
The full indication is: “Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in adults 50 years of age or older. The use of Shingrix should be in accordance with official recommendations”.
For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at firstname.lastname@example.org
We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.